ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CARM Carisma Therapeutics Inc

0.92
0.0368 (4.17%)
Pre Market
Last Updated: 09:02:40
Delayed by 15 minutes
Share Name Share Symbol Market Type
Carisma Therapeutics Inc NASDAQ:CARM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.0368 4.17% 0.92 0.8846 1.05 213 09:02:40

Carisma Therapeutics to Present at Upcoming Conferences

03/09/2024 12:30pm

PR Newswire (US)


Carisma Therapeutics (NASDAQ:CARM)
Historical Stock Chart


From Aug 2024 to Nov 2024

Click Here for more Carisma Therapeutics Charts.

PHILADELPHIA, Sept. 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the following upcoming conferences:

(PRNewsfoto/CARISMA Therapeutics Inc.)

Baird 2024 Global Healthcare Conference

  • Tuesday, September 10 at 12:50 PM ET
  • New York, NY

H.C. Wainwright 26th Annual Global Investment Conference

  • Wednesday, September 11 at 1:30 PM ET
  • New York, NY

Chardan's 8th Annual Genetic Medicines Conference

  • Monday, September 30 at 4:00 PM ET
  • New York, NY

The Cell & Gene Meeting on the Mesa

  • Monday, October 7 at 9:30 AM MST
  • Phoenix, AZ

Live webcasts will be available on the Company's Investor Events webpage. A replay of the webcasts, when available, will be archived for a limited time following the event.

About Carisma

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.

Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com

Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-present-at-upcoming-conferences-302235237.html

SOURCE Carisma Therapeutics Inc.

Copyright 2024 PR Newswire

1 Year Carisma Therapeutics Chart

1 Year Carisma Therapeutics Chart

1 Month Carisma Therapeutics Chart

1 Month Carisma Therapeutics Chart